Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of Astellas. FDA records under 4 spellings of its name, each linked to the record. See the Astellas group view.
As of Nov 16, 2026, FDA's public records list Astellas Pharma US with 5 drug recalls and 3 complete response letters. The most recent is a drug recall dated Dec 23, 2024: Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan,….
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Dec 23, 2024 | Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan, Distributed by: Astellas Pharma US, Inc., NorthbrooClass I · Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules | Drug recalls |
| Dec 23, 2024 | Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US IClass I · Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules | Drug recalls |
| Nov 15, 2024 | Complete response letter, NDA 217225/S-001Approved | Complete response letters |
| Jan 4, 2024 | Complete response letter, BLA 761365Approved | Complete response letters |
| Aug 28, 2017 | Complete response letter, NDA 209529Approved | Complete response letters |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built